Advertisement

Bupivacaine with epinephrine Injection

[02 December 2016]

Products Affected - Description

Bupivacaine (with epinephrine 1:200,000) injection, Hospira
0.25%, 10 mL vial, 50 count (NDC 00409-9042-01)
0.25%, 30 mL vial, 100 count (NDC 00409-9042-17)
0.25%, 50 mL vial, 25 count (NDC 00409-9043-01)
0.5%, 30 mL vial, 100 count (NDC 00409-9045-17)
0.5%, 50 mL vial, 25 count (NDC 00409-9046-01)

Marcaine (with epinephrine 1:200,000) injection, Hospira
0.25%, 10 mL vial, 10 count (NDC 00409-1746-10)
0.25%, 50 mL vial, 1 count (NDC 00409-1752-50)
0.5%, 30 mL vial, 10 count (NDC 00409-1749-29)
0.5%, 50 mL vial, 1 count (NDC 00409-1755-50)
 
Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi
0.25%, 10 mL vial, 25 count (NDC 63323-0468-17)
0.25%, 30 mL vial, 25 count (NDC 63323-0468-37)
0.5%, 10 mL vial, 25 count (NDC 63323-0462-17)
0.5%, 30 mL sterile pack vial, 5 count (NDC 63323-0462-31)
0.5%, 30 mL vial, 25 count (NDC 63323-0462-37)

Reason for the Shortage

Hospira has bupivacaine with epinephrine on shortage due to manufacturing delays.

Available Products

Bupivacaine (with epinephrine 1:200,000) injection, Hospira
0.5%, 10 mL vial, 50 count (NDC 00409-9045-01)
 
Marcaine (with epinephrine 1:200,000) injection, Hospira
0.25%, 30 mL vial, 10 count (NDC 00409-1746-30)
0.5%, 10 mL vial, 10 count (NDC 00409-1749-10)
 
Sensorcaine (with epinephrine 1:200,000) injection, Fresenius Kabi
0.25%, 50 mL vial, 25 count (NDC 63323-0461-57)
0.5%, 50 mL vial, 25 count (NDC 63323-0463-57)

Sensorcaine-MPF (with epinephrine 1:200,000) injection, Fresenius Kabi
0.75%, 30 mL vial, 25 count (NDC 63323-0460-37)

Estimated Resupply Dates

  • Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 10 mL vials and 0.5% Sensorcaine-MPF with epinephrine 10 mL vials on back order and the company estimates a release date of mid-April 2017. Fresenius Kabi has 0.25% Sensorcaine-MPF with epinephrine 30 mL vials on back order and the company estimates a release date of mid-January 2017. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials are on back order and the company estimates a release date of early-December 2016. The 0.5% Sensorcaine-MPF with epinephrine 30 mL vials sterile packs are on back order and the company estimates a release date of late-January 2017.
  • Hospira has 0.25% bupivacaine with epinephrine 30 mL vials and 0.5% bupivacaine with epinephrine 30 mL vials available in limited supply. The 0.25% bupivacaine with epinephrine 10 mL and 50 mL vials on back order and the company estimates a release date of mid-December 2016 for the 10 mL vials and late-December 2016 for the 50 mL vials. The 0.5% bupivacaine with epinephrine 50 mL vials are on back order and the company estimates a release date of late-December 2016.
  • Hospira has 0.25% Marcaine with epinephrine 10 mL vials available in limited supply. The 0.25% Marcaine 50 mL vials are on back order and the company estimates a release date of mid-January 2017. The 0.5% Marcaine 30 mL vials are on back order and the company estimates a release date of late-December 2016.The 0.5% Marcaine 50 mL vials are on back order and the company estimates a release date of late-January 2017.

Related Shortages

Updated

December 2, November 21, 11 and 7, October 19, September 27, 13 and 2, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing